{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:19:03Z","timestamp":1778642343040,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"31","license":[{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1038\/s41388-018-0274-4","type":"journal-article","created":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T09:13:32Z","timestamp":1525079612000},"page":"4226-4238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A modified gene trap approach for improved high-throughput cancer drug discovery"],"prefix":"10.1038","volume":"37","author":[{"given":"Shelli M.","family":"Morris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Mhyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savanna S.","family":"Carmack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie H.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connor","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Klinghoffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,2]]},"reference":[{"key":"274_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrc.2017.32","volume":"1","author":"WG Kaelin Jr","year":"2017","unstructured":"Kaelin WG Jr. Common pitfalls in preclinical cancer target validation. Nat Rev Cancer. 2017;1:425\u201340.","journal-title":"Nat Rev Cancer"},{"key":"274_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature04296","volume":"439","author":"AH Bild","year":"2006","unstructured":"Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006;439:353\u20137.","journal-title":"Nature"},{"key":"274_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-3-26","volume":"3","author":"A Loboda","year":"2010","unstructured":"Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, et al. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Med Genom. 2010;3:26.","journal-title":"BMC Med Genom"},{"key":"274_CR4","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1101\/gad.5.9.1513","volume":"5","author":"G Friedrich","year":"1991","unstructured":"Friedrich G, Soriano P. Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. Genes Dev. 1991;5:1513\u201323.","journal-title":"Genes Dev"},{"key":"274_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/0076-6879(93)25044-3","volume":"225","author":"G Friedrich","year":"1993","unstructured":"Friedrich G, Soriano P. Insertional mutagenesis by retroviruses and promoter traps in embryonic stem cells. Methods Enzymol. 1993;225:681\u2013701.","journal-title":"Methods Enzymol"},{"key":"274_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0076-6879(10)77013-0","volume":"477","author":"RH Friedel","year":"2010","unstructured":"Friedel RH, Soriano P. Gene trap mutagenesis in the mouse. Methods Enzymol. 2010;477:243\u201369.","journal-title":"Methods Enzymol"},{"key":"274_CR7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/89343","volume":"19","author":"E Medico","year":"2001","unstructured":"Medico E, Gambarotta G, Gentile A, Comoglio PM, Soriano P. A gene trap vector system for identifying transcriptionally responsive genes. Nat Biotechnol. 2001;19:579\u201382.","journal-title":"Nat Biotechnol"},{"key":"274_CR8","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Eng J Med. 2010;363:809\u201319.","journal-title":"N Eng J Med"},{"key":"274_CR9","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14:463\u201382.","journal-title":"Nat Rev Clin Oncol"},{"key":"274_CR10","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.1600-0749.2007.00375.x","volume":"20","author":"P Johansson","year":"2007","unstructured":"Johansson P, Pavey S, Hayward N. Confirmation of a BRAF mutation-associated gene expression signature in melanoma. Pigment Cell Res. 2007;20:216\u201321.","journal-title":"Pigment Cell Res"},{"key":"274_CR11","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1038\/sj.onc.1207563","volume":"23","author":"S Pavey","year":"2004","unstructured":"Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene. 2004;23:4060\u20137.","journal-title":"Oncogene"},{"key":"274_CR12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.molonc.2008.01.002","volume":"1","author":"C Kannengiesser","year":"2008","unstructured":"Kannengiesser C, Spatz A, Michiels S, Eychene A, Dessen P, Lazar V, et al. Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. Mol Oncol. 2008;1:425\u201330.","journal-title":"Mol Oncol"},{"key":"274_CR13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nature09454","volume":"467","author":"G Bollag","year":"2010","unstructured":"Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467:596\u20139.","journal-title":"Nature"},{"key":"274_CR14","first-page":"23","volume":"39","author":"T Yamaguchi","year":"2011","unstructured":"Yamaguchi T, Kakefuda R, Tajima N, Sowa Y, Sakai T. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1\/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol. 2011;39:23\u201331.","journal-title":"Int J Oncol"},{"key":"274_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1021\/ml200004g","volume":"2","author":"H Abe","year":"2011","unstructured":"Abe H, Kikuchi S, Hayakawa K, Iida T, Nagahashi N, Maeda K, et al. Discovery of a highly potent and selective MEK inhibitor: GSK1120212 (JTP-74057 DMSO Solvate). ACS Med Chem Lett. 2011;2:320\u20134.","journal-title":"ACS Med Chem Lett"},{"key":"274_CR16","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/sj.leu.2402464","volume":"16","author":"M Monga","year":"2002","unstructured":"Monga M, Sausville EA. Developmental therapeutics program at the NCI: molecular target and drug discovery process. Leukemia. 2002;16:520\u20136.","journal-title":"Leukemia"},{"key":"274_CR17","first-page":"7818","volume":"8","author":"YJ Li","year":"2015","unstructured":"Li YJ, He YF, Han XH, Hu B. Dasatinib suppresses invasion and induces apoptosis in nasopharyngeal carcinoma. Int J Clin Exp Pathol. 2015;8:7818\u201324.","journal-title":"Int J Clin Exp Pathol"},{"key":"274_CR18","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1038\/cddis.2016.360","volume":"7","author":"LA Mathews Griner","year":"2016","unstructured":"Mathews Griner LA, Zhang X, Guha R, McKnight C, Goldlust IS, Lal-Nag M, et al. Large-scale pharmacological profiling of 3D tumor models of cancer cells. Cell Death Dis. 2016;7:e2492.","journal-title":"Cell Death Dis"},{"key":"274_CR19","first-page":"1450","volume":"11","author":"FP Santos","year":"2010","unstructured":"Santos FP, Kantarjian H, Cortes J, Quintas-Cardama A. Bafetinib, a dual Bcr-Abl\/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Curr Opin Investig Drugs. 2010;11:1450\u201365.","journal-title":"Curr Opin Investig Drugs"},{"key":"274_CR20","doi-asserted-by":"publisher","first-page":"6478","DOI":"10.1021\/jm400778d","volume":"56","author":"M Okaniwa","year":"2013","unstructured":"Okaniwa M, Hirose M, Arita T, Yabuki M, Nakamura A, Takagi T, et al. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. J Med Chem. 2013;56:6478\u201394.","journal-title":"J Med Chem"},{"key":"274_CR21","doi-asserted-by":"publisher","first-page":"7043","DOI":"10.1158\/0008-5472.CAN-13-1825","volume":"73","author":"A Nakamura","year":"2013","unstructured":"Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, et al. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res. 2013;73:7043\u201355.","journal-title":"Cancer Res"},{"key":"274_CR22","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1021\/jm300126x","volume":"55","author":"M Okaniwa","year":"2012","unstructured":"Okaniwa M, Hirose M, Imada T, Ohashi T, Hayashi Y, Miyazaki T, et al. Design and synthesis of novel DFG-out RAF\/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds. J Med Chem. 2012;55:3452\u201378.","journal-title":"J Med Chem"},{"issue":"R1","key":"274_CR23","doi-asserted-by":"publisher","first-page":"R40","DOI":"10.1093\/hmg\/ddu125","volume":"23","author":"F Zhang","year":"2014","unstructured":"Zhang F, Wen Y, Guo X. CRISPR\/Cas9 for genome editing: progress, implications and challenges. Hum Mol Genet. 2014;23(R1):R40\u20136.","journal-title":"Hum Mol Genet"},{"key":"274_CR24","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc.2017.36","volume":"17","author":"CV Dang","year":"2017","unstructured":"Dang CV, Reddy EP, Shokat KM, Soucek L. Drugging the \u2018undruggable\u2019 cancer targets. Nat Rev Cancer. 2017;17:502\u20138.","journal-title":"Nat Rev Cancer"},{"key":"274_CR25","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13:828\u201351.","journal-title":"Nat Rev Drug Discov"},{"key":"274_CR26","unstructured":"Kalkat M, De Melo J, Hickman KA, Lourenco C, Redel C, Resetca D, et al. MYC deregulation in primary human cancers. Genes. 2017;8, 151."},{"key":"274_CR27","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0022-2836(05)80360-2","volume":"215","author":"SF Altschul","year":"1990","unstructured":"Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990;215:403\u201310.","journal-title":"J Mol Biol"},{"key":"274_CR28","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/bioinformatics\/btp120","volume":"25","author":"C Trapnell","year":"2009","unstructured":"Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25:1105\u201311.","journal-title":"Bioinformatics"},{"key":"274_CR29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166\u20139.","journal-title":"Bioinformatics"},{"key":"274_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139\u201340.","journal-title":"Bioinformatics"},{"key":"274_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2174\/1875397301004010057","volume":"4","author":"Y Wang","year":"2010","unstructured":"Wang Y, Jadhav A, Southal N, Huang R, Nguyen DT. A grid algorithm for high throughput fitting of dose-response curve data. Curr Chem Genom. 2010;4:57\u201366.","journal-title":"Curr Chem Genom"},{"key":"274_CR32","doi-asserted-by":"publisher","first-page":"11473","DOI":"10.1073\/pnas.0604348103","volume":"103","author":"J Inglese","year":"2006","unstructured":"Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, Yasgar A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci USA. 2006;103:11473\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"274_CR33","unstructured":"Southall N, Jadhav A, Huang R, Nguyen T, Wang Y. Enabling the large scale analysis of quantitative high throughput screening data. In: Seethala R, Zhang L, editors. Handbook of Drug Screening. Second ed. Boca Raton, FL, USA: CRC Press; 2009. p. 442\u201364."},{"key":"274_CR34","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","volume":"106","author":"S Kimura","year":"2005","unstructured":"Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, et al. NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood. 2005;106:3948\u201354.","journal-title":"Blood"},{"key":"274_CR35","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","volume":"17","author":"AG Gilmartin","year":"2011","unstructured":"Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res. 2011;17:989\u20131000.","journal-title":"Clin Cancer Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0274-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0274-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0274-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:11:40Z","timestamp":1684617100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-018-0274-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,2]]},"references-count":35,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["274"],"URL":"https:\/\/doi.org\/10.1038\/s41388-018-0274-4","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,2]]},"assertion":[{"value":"12 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S.M.M. and J.M.O. are shareholders in Presage Biosciences and J.M.O. serves on the Presage Board. R.A.K. and C.B. are employees and shareholders of Presage Biosciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}